SCYX Q4 2024 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$977,000-83.1% YoY

Gross Profit

$977,000100.0% margin

Operating Income

-$8M-824.3% margin

Net Income

-$4M-453.7% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+48.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$981,000

Balance Sheet

Total Assets

$91M

Total Liabilities

$36M

Stockholders' Equity

$55M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$977,000	$6M	-83.1%
Gross Profit	$977,000	-$9M	+111.0%
Operating Income	-$8M	-$23M	+65.1%
Net Income	-$4M	-$20M	+77.4%

Revenue Segments

License and Service

$3M100%